NeuroDiscovery AI Launches NeuroTerminal Platform for Neurology Research

NeuroDiscovery AI has introduced NeuroTerminal, a platform built for neurology research that integrates modules for clinical trials, real world evidence, and medical affairs. The launch was announced in a press release on May 19, 2026.

NeuroTerminal is designed to improve patient access to therapies for neurological disorders such as Alzheimer's disease, Parkinson's disease, migraine, multiple sclerosis, epilepsy, and rare conditions. The platform uses one of the largest neurology focused real world datasets in the United States, including over six million de-identified patient journeys and more than three million patients eligible for clinical trials.

The system connects more than one thousand neurologists and advanced practice providers across one hundred clinical sites in sixteen states. It aims to reduce the time needed to identify and screen patients for clinical trials from several months to a few weeks.

Beyond recruitment, NeuroTerminal supports real world data licensing, evidence generation, provider engagement, and commercialization support. The company is collaborating with pharmaceutical sponsors, clinical research organizations, and neurology providers to improve research efficiency and expand access to new therapies.